Drug · FAERS side-effect profile with label screen
Loratadine and Pseudoephedrine side effects: what 7,906 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Loratadine (Loratadine)
closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match
Who reports
7,906 reports · 21% serious · 88 with death outcome · 69% female
openFDA FAERS counts, all years, deduplication not applied
Used for
(S) temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, water eyes itching of the nose or throat
FDA label, Indications and Usage
Boxed warning
None in the current label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation.
Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)?
That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.
Causality screen of the 40 strongest signals
Reporting / coding artifact 11Lab value / disease marker 3No label text to screen 26
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 960 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
Show:
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug effect delayed | 82 | 48.1 38.7–59.8ROR 48.6 · χ² 3,672 / p <1e-300 | 46.8 EB05 38.9 · IC025 +4.8 3/3 methods agree | Reporting / coding artifact | 100% consumer | no trial data cached |
| Amphetamines positive | 10 | 35.5 19.0–66.2ROR 35.5 · χ² 298 / p 5e-67 | 33.0 EB05 19.1 · IC025 +2.7 3/3 methods agree | Lab value / disease marker | – | no trial data cached |
| Drug effect decreased | 454 | 22.2 20.3–24.3ROR 23.5 · χ² 9,122 / p <1e-300 | 22.0 EB05 20.4 · IC025 +4.3 3/3 methods agree | Reporting / coding artifact | serious PRR 7.5 · 98% consumer | no trial data cached |
| Feeling jittery | 149 | 20.9 17.8–24.5ROR 21.2 · χ² 2,776 / p <1e-300 | 20.6 EB05 18.0 · IC025 +4.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=11 · 99% consumer | no trial data cached |
| Nasal dryness | 38 | 16.2 11.8–22.2ROR 16.2 · χ² 523 / p 6e-116 | 15.9 EB05 12.0 · IC025 +3.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | 95% consumer | no trial data cached |
| Expired drug administered | 25 | 13.3 9.0–19.6ROR 13.3 · χ² 270 / p 5e-61 | 12.7 EB05 8.7 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious n=2 · 100% consumer | no trial data cached |
| Poor quality sleep | 95 | 11.8 9.7–14.4ROR 12.0 · χ² 927 / p 6e-204 | 11.6 EB05 9.7 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | serious PRR 1.9 · 100% consumer | no trial data cached |
| Accidental exposure to product by child | 30 | 11.7 8.2–16.7ROR 11.7 · χ² 282 / p 1e-63 | 11.1 EB05 7.9 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | ♀ 48% (drug 69%) · 70% consumer | no trial data cached |
| Energy increased | 22 | 9.9 6.5–15.0ROR 9.9 · χ² 166 / p 3e-38 | 8.9 EB05 5.9 · IC025 +2.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | 100% consumer | no trial data cached |
| Extra dose administered | 118 | 7.9 6.6–9.4ROR 8.0 · χ² 699 / p 2e-154 | 7.7 EB05 6.6 · IC025 +2.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | 76% consumer | no trial data cached |
| Therapeutic product ineffective | 11 | 7.5 4.1–13.5ROR 7.5 · χ² 55 / p 6e-14 | 5.9 EB05 3.5 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Cholecystitis chronic | 19 | 7.4 4.7–11.7ROR 7.5 · χ² 99 / p 1e-23 | 6.5 EB05 4.3 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 20.8 | no trial data cached |
| Drug screen positive | 22 | 7.4 4.9–11.3ROR 7.4 · χ² 116 / p 3e-27 | 6.6 EB05 4.5 · IC025 +2.0 3/3 methods agree | Lab value / disease marker | serious n=3 · 100% consumer | no trial data cached |
| Insomnia (trouble sleeping) | 719 | 7.2 6.7–7.7ROR 7.8 · χ² 3,847 / p <1e-300 | 7.1 EB05 6.7 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.2 · 94% consumer | no trial data cached |
| Incorrect product administration duration | 54 | 7.1 5.4–9.2ROR 7.1 · χ² 275 / p 4e-62 | 6.7 EB05 5.3 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | 100% consumer | no trial data cached |
| Paranasal sinus discomfort | 10 | 7.1 3.8–13.1ROR 7.1 · χ² 46 / p 6e-12 | 5.5 EB05 3.2 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=3 | no trial data cached |
| Expired product administered | 87 | 7.0 5.7–8.6ROR 7.0 · χ² 438 / p 1e-97 | 6.7 EB05 5.6 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | 95% consumer | no trial data cached |
| Psychomotor hyperactivity | 43 | 6.9 5.1–9.2ROR 6.9 · χ² 209 / p 1e-47 | 6.4 EB05 5.0 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 8.2 · 92% consumer | no trial data cached |
| Dry throat | 25 | 6.5 4.4–9.7ROR 6.6 · χ² 112 / p 2e-26 | 5.9 EB05 4.2 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=5 · ♀ 91% (drug 69%) · 100% consumer | no trial data cached |
| Nervousness | 127 | 6.4 5.4–7.6ROR 6.5 · χ² 577 / p 1e-127 | 6.3 EB05 5.4 · IC025 +2.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.3 · 91% consumer | no trial data cached |
| Therapeutic response unexpected | 107 | 6.3 5.2–7.6ROR 6.4 · χ² 473 / p 3e-105 | 6.1 EB05 5.2 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | serious PRR 4.5 · 97% consumer | no trial data cached |
| Dry mouth | 187 | 6.1 5.3–7.1ROR 6.3 · χ² 800 / p 3e-176 | 6.0 EB05 5.3 · IC025 +2.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.9 · 93% consumer | no trial data cached |
| Onychomycosis | 10 | 6.1 3.3–11.3ROR 6.1 · χ² 37 / p 5e-10 | 4.9 EB05 2.8 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=7 | no trial data cached |
| Dysuria (painful urination) | 81 | 5.8 4.7–7.3ROR 5.9 · χ² 320 / p 7e-72 | 5.7 EB05 4.7 · IC025 +2.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 7.8 · ♀ 22% (drug 69%) · 85% consumer | no trial data cached |
| Product use issue | 383 | 5.4 4.9–6.0ROR 5.7 · χ² 1,394 / p <1e-300 | 5.4 EB05 5.0 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | serious PRR 1.3 · 96% consumer | no trial data cached |
| Thirst | 36 | 5.4 3.9–7.4ROR 5.4 · χ² 123 / p 6e-29 | 5.0 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.9 · 91% consumer | no trial data cached |
| Sneezing | 44 | 5.2 3.9–7.0ROR 5.3 · χ² 146 / p 6e-34 | 5.0 EB05 3.8 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.8 · 91% consumer | no trial data cached |
| Drug effect incomplete | 72 | 5.2 4.1–6.5ROR 5.2 · χ² 239 / p 3e-54 | 5.0 EB05 4.1 · IC025 +1.9 3/3 methods agree | Reporting / coding artifact | 96% consumer | no trial data cached |
| Euphoric mood | 20 | 5.2 3.3–8.0ROR 5.2 · χ² 63 / p 1e-15 | 4.6 EB05 3.2 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=8 | no trial data cached |
| Pre-existing condition improved | 12 | 5.1 2.9–8.9ROR 5.1 · χ² 35 / p 2e-9 | 4.3 EB05 2.6 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Tricuspid valve incompetence | 15 | 5.0 3.0–8.4ROR 5.0 · χ² 45 / p 1e-11 | 4.4 EB05 2.9 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 14.2 | no trial data cached |
| Initial insomnia | 19 | 4.9 3.2–7.8ROR 5.0 · χ² 56 / p 4e-14 | 4.4 EB05 3.0 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Product packaging issue | 17 | 4.9 3.0–7.8ROR 4.9 · χ² 48 / p 2e-12 | 4.3 EB05 2.9 · IC025 +1.3 3/3 methods agree | Reporting / coding artifact | serious n=5 | no trial data cached |
| Nasal discomfort | 14 | 4.7 2.8–7.9ROR 4.7 · χ² 37 / p 7e-10 | 4.1 EB05 2.6 · IC025 +1.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Palpitations (pounding heartbeat) | 201 | 4.6 4.0–5.2ROR 4.7 · χ² 558 / p 1e-123 | 4.5 EB05 4.0 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.7 · 92% consumer | no trial data cached |
| Mitral valve incompetence | 19 | 4.5 2.8–7.0ROR 4.5 · χ² 48 / p 3e-12 | 4.1 EB05 2.8 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 12.6 | no trial data cached |
| Seasonal allergy | 22 | 4.1 2.7–6.3ROR 4.1 · χ² 49 / p 1e-12 | 3.8 EB05 2.7 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=8 | no trial data cached |
| Heart rate increased | 146 | 3.9 3.3–4.6ROR 4.0 · χ² 315 / p 9e-71 | 3.9 EB05 3.4 · IC025 +1.7 3/3 methods agree | Lab value / disease marker | serious PRR 5.2 · 89% consumer | no trial data cached |
| Lacrimation increased | 44 | 3.9 2.9–5.3ROR 3.9 · χ² 92 / p 4e-22 | 3.8 EB05 2.9 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 3.2 · 86% consumer | no trial data cached |
| Spinal osteoarthritis | 13 | 3.9 2.3–6.7ROR 3.9 · χ² 25 / p 2e-7 | 3.5 EB05 2.2 · IC025 +0.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 10.9 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 1,751 | 3.5 3.4–3.7ROR 4.3 · χ² 3,382 / p <1e-300 | 3.5 EB05 3.4 · IC025 +1.7 3/3 methods agree | Reporting / coding artifact | serious PRR 1.1 · 97% consumer | no trial data cached |
| Insomnia (trouble sleeping) | 719 | 7.2 6.7–7.7ROR 7.8 · χ² 3,847 / p <1e-300 | 7.1 EB05 6.7 · IC025 +2.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.2 · 94% consumer | no trial data cached |
| Drug effect decreased | 454 | 22.2 20.3–24.3ROR 23.5 · χ² 9,122 / p <1e-300 | 22.0 EB05 20.4 · IC025 +4.3 3/3 methods agree | Reporting / coding artifact | serious PRR 7.5 · 98% consumer | no trial data cached |
| Product use issue | 383 | 5.4 4.9–6.0ROR 5.7 · χ² 1,394 / p <1e-300 | 5.4 EB05 5.0 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | serious PRR 1.3 · 96% consumer | no trial data cached |
| Dizziness | 376 | 2.0 1.8–2.2ROR 2.1 · χ² 193 / p 4e-44 | 2.0 EB05 1.8 · IC025 +0.8 | No label text to screen label has no adverse-reaction text | serious PRR 3.5 · 82% consumer | no trial data cached |
| Somnolence (drowsiness) | 294 | 3.9 3.5–4.3ROR 4.0 · χ² 632 / p 1e-139 | 3.9 EB05 3.5 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.4 · 92% consumer | no trial data cached |
| Headache | 283 | 1.2 1.1–1.3ROR 1.2 · χ² 9 / p 0.001 | 1.2 EB05 1.1 · IC025 +0.1 | No label text to screen label has no adverse-reaction text | serious PRR 2.5 · 76% consumer | no trial data cached |
| Nausea | 279 | 0.9 0.8–1.1ROR 0.9 · χ² 1 / p 0.144 | 0.9 EB05 0.9 · IC025 -0.3 PRR-only: not supported by EBGM or IC | No label text to screen label has no adverse-reaction text | serious PRR 2.3 · 75% consumer | no trial data cached |
| Fatigue (tiredness) | 255 | 0.9 0.8–1.0ROR 0.9 · χ² 5 / p 0.013 | 0.9 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC | No label text to screen label has no adverse-reaction text | serious PRR 2.0 | no trial data cached |
| Dyspnoea (shortness of breath) | 230 | 1.1 0.9–1.2ROR 1.1 · χ² 1 / p 0.129 | 1.1 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC | No label text to screen label has no adverse-reaction text | serious PRR 2.8 | no trial data cached |
| Feeling abnormal | 217 | 2.4 2.1–2.7ROR 2.4 · χ² 177 / p 1e-40 | 2.4 EB05 2.1 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 2.6 · 93% consumer | no trial data cached |
| Palpitations (pounding heartbeat) | 201 | 4.6 4.0–5.2ROR 4.7 · χ² 558 / p 1e-123 | 4.5 EB05 4.0 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 5.7 · 92% consumer | no trial data cached |
| Dry mouth | 187 | 6.1 5.3–7.1ROR 6.3 · χ² 800 / p 3e-176 | 6.0 EB05 5.3 · IC025 +2.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 4.9 · 93% consumer | no trial data cached |
| Off label use (used outside approved label) | 184 | 0.6 0.5–0.6ROR 0.6 · χ² 65 / p 4e-16 | 0.6 EB05 0.5 · IC025 -1.1 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 0.4 · 92% consumer | no trial data cached |
| Anxiety | 182 | 1.7 1.5–2.0ROR 1.7 · χ² 52 / p 3e-13 | 1.7 EB05 1.5 · IC025 +0.5 | No label text to screen label has no adverse-reaction text | serious PRR 3.9 · 72% consumer | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Loratadine and Pseudoephedrine?
In FDA FAERS, the most frequently co-reported reaction terms for Loratadine and Pseudoephedrine are insomnia, dizziness, somnolence, headache, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Loratadine and Pseudoephedrine have an FDA boxed warning?
No. The FDA label retrieved for Loratadine and Pseudoephedrine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Loratadine and Pseudoephedrine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0d74af21-3ef7-418b-a2ef-78737b0af288, effective 20250613; matched on
openfda.generic_name.exact:"LORATADINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,000 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.